Evidence map›Paper›PMID 27746282›Full record

ArticleThe Journal of urology2017

Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (

Tore Bach-Gansmo, Cristina Nanni, Peter T Nieh, Lucia Zanoni, Tronde Velde Bogsrud, Heidi Sletten, Katrine Andersen Korsan, J Kieboom, Funmilayo I Tade, Oluwaseun Odewole and 6 more

3 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 71 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02443571 completednot on this map

A Retrospective Observational Study Investigating the Safety and Effectiveness of Fluciclovine (18F) (FACBC) PET Ligand in Human Subjects

TypeobservationalSponsorBlue Earth DiagnosticsRan2015 to 2015Enrolled714ConditionsProstatic NeoplasmsArmsFluciclovine (18F)
NCT04234399 terminatednot on this mapstarted 2020, after this paper: background citation

Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) PET/CT Utilizing the High Resolution Digital Philips Vereos Scanner, in Patients With Biochemical Recurrence After Radical Prostatectomy

TypeobservationalSponsorUniversity of VermontRan2020 to 2024Enrolled22ConditionsProstatic NeoplasmArmsFluciclovine PET/CT using a digital PET/CT
NCT05936658 phase3active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

TypeinterventionalSponsorFutureChemRan2023 to 2025Enrolled138ConditionsHigh Risk Prostate CarcinomaArms[F-18]Florastamin
3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. The Diagnostic Role ofFrontiers in oncology · 2021
    Pooled it
  4. [European journal of nuclear medicine and molecular imaging · 2020
    Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. [Tomography (Ann Arbor, Mich.) · 2022
    Trial
  9. [European journal of nuclear medicine and molecular imaging · 2021
    Trial
  10. Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Trial
  11. [The Journal of urology · 2020
    Trial
  12. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Trial
  13. The Lancet. Oncology · 2019
    Trial
  14. Trial
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Tore Bach-GansmoDepartment of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway. Electronic address: bat@uus.no.
Cristina NanniNuclear Medicine, Azienda ospedaliero-universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy.
Peter T NiehDepartment of Urology, Emory University, Atlanta, Georgia.
Lucia ZanoniNuclear Medicine, Azienda ospedaliero-universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy.
Tronde Velde BogsrudDepartment of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Heidi SlettenDepartment of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Katrine Andersen KorsanDepartment of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
J KieboomDepartment of Nuclear Medicine and Radiology, Aleris Healthcare, Oslo, Norway.
Funmilayo I TadeDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Oluwaseun OdewoleDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Albert ChauBlue Earth Diagnostics, Oxford, United Kingdom.
Penelope WardBlue Earth Diagnostics, Oxford, United Kingdom.
Mark M GoodmanDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Stefano FantiNuclear Medicine, Azienda ospedaliero-universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy.
David M SchusterDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Frode WillochDepartment of Nuclear Medicine and Radiology, Aleris Healthcare, Oslo, Norway; Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.

Funding

18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate CarcinomaR01CA129356 · NCI · EMORY UNIVERSITY · PI SCHUSTER, DAVID MICHAEL · 2007 to 2011
$1.6M
NCI NIH HHS R01 CA129356
6 · The paper itself

Abstract

purposeSensitive detection of cancer foci in men experiencing biochemical recurrence following initial treatment of prostate cancer is of great clinical significance with a possible impact on subsequent treatment choice. We describe a multisite experience of the efficacy and safety of the positron emission tomography/computerized tomography agent fluciclovine ( MATERIALS AND

methodsA total of 596 patients underwent fluciclovine (

resultsThe subject level fluciclovine (

conclusionsFluciclovine (

Indexed as

Carboxylic AcidsCyclobutanesPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overHumansMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesCarboxylic AcidsCyclobutanesfluciclovine F-18Prostate-Specific Antigenemission-computedfluciclovine F-18localneoplasm recurrencepositron-emission tomographyprostatic neoplasmstomography

Identifiers

PMID27746282
PMCPMC5645081

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.